Pay in 4 interest-free payments of $6.61 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
This is a combination product that contains both insulin glargine and lixisenatide, which is a GLP-1 receptor agonist
When families and employers make a significant investment, we want the result to improve health
However, results vary depending on adherence and baseline metabolic function
For patients considering metformin and semaglutide combination therapy, integrating genetic insights into a broader clinical pictureincluding HbA1c levels, BMI, kidney function, and cardiovascular riskcan help facilitate more personalized treatment conversations
The Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) phase 3 programme demonstrated the efficacy of oral semaglutide versus placebo and active comparators (including empagliflozin, sitagliptin and liraglutide) in achieving glycaemic control and weight loss, with a safety profile consistent with the GLP-1RA drug class [10,11,12,13,14,15,16,17,18,19,20,21]
US$ 20.44
US$ 23.83
US$ 22.26
US$ 27.07
US$ 22.63
US$ 26.37
US$ 28.65
US$ 22.69
US$ 26.68
US$ 22.73
US$ 25.42
US$ 25.72
